Professor Eric W Lam

Publications


Journals

  • Di Fruscia P; Ho K-K; Laohasinnarong S; Khonghow M; Kroll SHB; Islam SA; Sternberg MJE; Schmidtkunz K; et alJung M; Lam EW-F; Fuchter MJ. (4 Jan 2012). The discovery of novel 10,11-dihydro-5H-dibenz[b,f]azepine SIRT2 inhibitors. MedChemComm. DOI.
  • Down CF; Millour J; Lam EW; Watson RJ. (30 Mar 2012). Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. Biochim Biophys Acta. DOI.
  • Ferrari-Amorotti G; Mariani SA; Novi C; Cattelani S; Pecorari L; Corradini F; Soliera AR; Manzotti G; et alFragliasso V; Zhang Y; Martinez RV; Lam EW-F; Guerzoni C; Calabretta B. (1 Oct 2010). The Biological Effects of C/EBP alpha in K562 Cells Depend on the Potency of the N-terminal Regulatory Region, Not on Specificity of the DNA Binding Domain. JOURNAL OF BIOLOGICAL CHEMISTRY. 285:30837-30850. DOI.
  • Hartman J; Lam EW-F; Gustafsson J-A; Strom A. (1 Jan 2009). Hes-6, an inhibitor of Hes-1, is regulated by 17 beta-estradiol and promotes breast cancer cell proliferation. BREAST CANCER RESEARCH. 11. DOI.
  • Zhao C; Matthews J; Tujague M; Wan J; Strom A; Toresson G; Lam EW-F; Cheng G; et alGustafsson J-A; Dahlman-Wright K. (15 Apr 2007). Estrogen receptor beta 2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. CANCER RESEARCH. 67:3955-3962. DOI.
  • White PC; Shore AM; Clement M; McLaren J; Soeiro I; Lam EWF; Brennan P. (1 Apr 2006). Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. ONCOGENE. 25:2170-2180. DOI.
  • Coffer PJ; Dijkers PF; Lam EWF; Lammers JWJ; Koenderman L. (16 Nov 2001). The forkhead transcription factor FKHR-L1 is a critical effector of cell death induced by cytokine withdrawal. BLOOD. 98:758A-758A.
  • Jiang L; Siu MK; Wong OG; Tam KF; Lu X; Lam EW; Ngan HY; Le XF; et alWong ES; Monteiro LJ; Chan HY; Cheung AN. (1 Nov 2011). iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe. Clin Cancer Res. 17:6924-6933. DOI.
  • Jiang L; Siu MK; Wong OG; Tam KF; Lam EW; Ngan HY; Le XF; Wong ES; et alChan HY; Cheung AN. (2010). Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Mol Cancer. 9:318. DOI.
  • Mena AL; Lam EW; Chatterjee S. (2010). Sustained spindle-assembly checkpoint response requires de novo transcription and translation of cyclin B1. PLoS One. 5. DOI.
  • Chen J; Gomes AR; Monteiro LJ; Wong SY; Wu LH; Ng TT; Karadedou CT; Millour J; et alIp YC; Cheung YN; Sunters A; Chan KY; Lam EW; Khoo US. (2010). Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS One. 5:e12293. DOI.
  • Alao JP; Stavropoulou AV; Lam EW; Coombes RC. (2006). Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol Cancer. 5:40. DOI.
  • Mckie AB; Vaughan S; Zanini E; Okon IS; Louis L; de Sousa C; Greene MI; Wang Q; et alAgarwal R; Shaposhnikov D; Wong JLS; Gungor H; Janczar S; El-Bahrawy M; Lam E-F; Chayen NE; Gabra H. (Feb 2012). The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer. Cancer Discovery. DOI.
  • Voorhoeve PM; Watson RJ; Farlie PG; Bernards R; Lam EWF. (21 Jan 1999). Rapid dephosphorylation of p107 following UV irradiation. ONCOGENE. 18:679-688. Author weblink DOI.
  • Kenny LM; Lam EW. (Jun 2011). Review: lapatinib in metastatic colorectal cancer-another strategy for disease control?. Clin Adv Hematol Oncol. 9:500-501.
  • Al-Sabbagh M; Lam EW; Brosens JJ. (9 Nov 2011). Mechanisms of endometrial progesterone resistance. Mol Cell Endocrinol. DOI.
  • Koo C-Y; Muir KW; Lam EW-F. (1 Jan 2012). FOXM1: From cancer initiation to progression and treatment. BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS. 1819:28-37. Author weblink DOI.
  • Ho K-K; McGuire VA; Koo C-Y; Muir KW; de Olano N; Maifoshie E; Kelly DJ; McGovern UB; et alMonteiro LJ; Gomes AR; Nebreda AR; Campbell DG; Arthur JSC; Lam EW-F. (6 Jan 2012). Phosphorylation of FOXO3a on Ser-7 by p38 Promotes Its Nuclear Localization in Response to Doxorubicin. JOURNAL OF BIOLOGICAL CHEMISTRY. 287:1545-1555. DOI.
  • Schmidt M; de Mattos SF; van der Horst A; Klompmaker R; Kops GJPL; Lam EWF; Burgering BMT; Medema RH. (1 Nov 2002). Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. MOLECULAR AND CELLULAR BIOLOGY. 22:7842-7852. Author weblink DOI.
  • Birkenkamp KU; Essafi A; van der Vos KE; da Costa M; Hui RC-Y; Holstege F; Koenderman L; Lam EW-F; et alCoffer PJ. (26 Jan 2007). FOXO3a induces differentiation of Bcr-Abl- transformed cells through transcriptional down-regulation of Id1. JOURNAL OF BIOLOGICAL CHEMISTRY. 282:2211-2220. Author weblink DOI.
  • Delpuech O; Griffiths B; East P; Essafi A; Lam EW-F; Burgering B; Downward J; Schulze A. (1 Jul 2007). Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. MOLECULAR AND CELLULAR BIOLOGY. 27:4917-4930. Author weblink DOI.
  • Myatt SS; Lam EW-F. (1 Mar 2008). Targeting FOXM1. NATURE REVIEWS CANCER. 8:244-244. Author weblink.
  • Ho KK; Myatt SS; Lam EW-F. (7 Apr 2008). Many forks in the path: cycling with FoxO. ONCOGENE. 27:2300-2311. Author weblink DOI.
  • Li SKM; Smith DK; Leung WY; Cheung AMS; Lam EWF; Dimri GP; Yao K-M. (13 Jun 2008). FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. JOURNAL OF BIOLOGICAL CHEMISTRY. 283:16545-16553. Author weblink DOI.
  • Fernandez de Mattos S; Villalonga P; Clardy J; Lam EW-F. (1 Oct 2008). FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. MOLECULAR CANCER THERAPEUTICS. 7:3237-3246. Author weblink DOI.
  • Bertoli C; Copetti T; Lam EW-F; Demarchi F; Schneider C. (5 Feb 2009). Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. ONCOGENE. 28:721-733. Author weblink DOI.
  • Serpa J; Caiado F; Carvalho T; Torre C; Goncalves LG; Casalou C; Lamosa P; Rodrigues M; et alZhu Z; Lam EWF; Dias S. (1 Dec 2010). Butyrate-rich Colonic Microenvironment Is a Relevant Selection Factor for Metabolically Adapted Tumor Cells. JOURNAL OF BIOLOGICAL CHEMISTRY. 285:39211-39223. Author weblink DOI.
  • van Loosdregt J; Brunen D; Fleskens V; Pals CEGM; Lam EWF; Coffer PJ. (20 Apr 2011). Rapid Temporal Control of Foxp3 Protein Degradation by Sirtuin-1. PLOS ONE. 6. Author weblink DOI.
  • Christian M; Lam EW-F; Wilson MSC; Brosens JJ. (1 Aug 2011). FOXO Transcription Factors and their Role in Disorders of the Female Reproductive Tract. CURRENT DRUG TARGETS. 12:1291-1302.
  • Wilson MSC; Brosens JJ; Schwenen HDC; Lam EW-F. (1 Aug 2011). FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy. CURRENT DRUG TARGETS. 12:1256-1266.
  • Karadedou CT; Gomes AR; Chen J; Petkovic M; Ho KK; Zwolinska AK; Feltes A; Wong SY; et alChan KY; Cheung YN; Tsang JW; Brosens JJ; Khoo US; Lam EW. (22 Aug 2011). FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene. DOI.
  • Horimoto Y; Hartman J; Millour J; Pollock S; Olmos Y; Ho KK; Coombes RC; Poutanen M; et alMäkelä SI; El-Bahrawy M; Speirs V; Lam EW. (Sep 2011). ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer. Am J Pathol. 179:1148-1156. DOI.
  • Millour J; De ON; Horimoto Y; Monteiro LJ; Langer J; Aligue R; Hajji NALE. ATM and p53 regulate FOXM1 expression via E2F in breast cancer pirubicin treatment and resistance. Molecular Cancer Therapeutics (in press).
  • Christian M; Lam EW; Wilson MS; Brosens JJ. (Aug 2011). FOXO transcription factors and their role in disorders of the female reproductive tract. Curr Drug Targets. 12:1291-1302.
  • Wilson MS; Brosens JJ; Schwenen HD; Lam EW. (Aug 2011). FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr Drug Targets. 12:1256-1266.
  • Lam EW; Shah K; Brosens JJ. (Jan 2012). The diversity of sex steroid action: the role of micro-RNAs and FOXO transcription factors in cycling endometrium and cancer. J Endocrinol. 212:13-25. DOI.
  • Olmos Y; Brosens JJ; Lam EW. (Feb 2011). Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist Updat. 14:35-44. DOI.
  • Serpa J; Caiado F; Carvalho T; Torre C; Gonçalves LG; Casalou C; Lamosa P; Rodrigues M; et alZhu Z; Lam EW; Dias S. (10 Dec 2010). Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells. J Biol Chem. 285:39211-39223. DOI.
  • Al-Sabbagh M; Fusi L; Higham J; Lee Y; Lei K; Hanyaloglu AC; Lam EW; Christian M; et alBrosens JJ. (Feb 2011). NADPH oxidase-derived reactive oxygen species mediate decidualization of human endometrial stromal cells in response to cyclic AMP signaling. Endocrinology. 152:730-740. DOI.
  • Myatt SS; Brosens JJ; Lam EW. (15 Feb 2011). Sense and sensitivity: FOXO and ROS in cancer development and treatment. Antioxid Redox Signal. 14:675-687. DOI.
  • Brosens JJ; Wilson MSC; Lam EW-F. Maiese K (ed). (1 Jan 2009). FOXO Transcription Factors: From Cell Fate Decisions to Regulation of Human Female Reproduction. FORKHEAD TRANSCRIPTION FACTORS: VITAL ELEMENTS IN BIOLOGY AND MEDICINE. 665:227-241. Author weblink.
  • Peck B; Chen CY; Ho KK; Di Fruscia P; Myatt SS; Coombes RC; Fuchter MJ; Hsiao CD; et alLam EW. (Apr 2010). SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 9:844-855. DOI.
  • Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; et alMedema RH; Hartman J; Lykkesfeldt AE; Lam EW. (20 May 2010). FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene. 29:2983-2995. DOI.
  • Vianello F; Villanova F; Tisato V; Lymperi S; Ho KK; Gomes AR; Marin D; Bonnet D; et alApperley J; Lam EW; Dazzi F. (Jul 2010). Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica. 95:1081-1089. DOI.
  • Kwok JM; Peck B; Monteiro LJ; Schwenen HD; Millour J; Coombes RC; Myatt SS; Lam EW. (Jan 2010). FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res. 8:24-34. DOI.
  • Hussain F; Wang J; Ahmed R; Guest SK; Lam EW; Stamp G; El-Bahrawy M. (Feb 2010). The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine. 49:134-140. DOI.
  • Leitao B; Jones MC; Fusi L; Higham J; Lee Y; Takano M; Goto T; Christian M; et alLam EW; Brosens JJ. (May 2010). Silencing of the JNK pathway maintains progesterone receptor activity in decidualizing human endometrial stromal cells exposed to oxidative stress signals. FASEB J. 24:1541-1551. DOI.
  • Myatt SS; Wang J; Monteiro LJ; Christian M; Ho KK; Fusi L; Dina RE; Brosens JJ; et alGhaem-Maghami S; Lam EW. (1 Jan 2010). Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 70:367-377. DOI.
  • Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; et alLopes N; Lam EW; Lunet N; Schmitt F. (1 Jan 2009). Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. BREAST CANCER RESEARCH. 11. Author weblink DOI.
  • Ho KK; Rosivatz E; Gunn RM; Smith ME; Stavropoulou AV; Rosivatz E; Numbere MG; Wong JB; et alLafitte VG; Behrendt JM; Myatt SS; Hailes HC; Woscholski R; Lam EW. (Aug 2009). The novel molecule 2-[5-(2-chloroethyl)-2-acetoxy-benzyl]-4-(2-chloroethyl)-phenyl acetate inhibits phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells. FEBS J. 276:4037-4050. DOI.
  • Francis RE; Myatt SS; Krol J; Hartman J; Peck B; McGovern UB; Wang J; Guest SK; et alFilipovic A; Gojis O; Palmieri C; Peston D; Shousha S; Yu Q; Sicinski P; Coombes RC; Lam EW. (Jul 2009). FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol. 35:57-68.
  • Fernández de Mattos S; Villalonga P; Clardy J; Lam EW. (Oct 2008). FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Mol Cancer Ther. 7:3237-3246.
  • Bertoli C; Copetti T; Lam EW; Demarchi F; Schneider C. (Feb 2009). Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. Oncogene. 28:721-733.
  • Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI. (Mar 2009). BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Blood. 113:2302-2311.
  • Batlle A; Papadopoulou V; Gomes AR; Willimott S; Melo JV; Naresh K; Lam EW; Wagner SD. (May 2009). CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression. Mol Immunol. 46:1727-1735. DOI.
  • McGovern UB; Francis RE; Peck B; Guest SK; Wang J; Myatt SS; Krol J; Kwok JM; et alPolychronis A; Coombes RC; Lam EW. (Mar 2009). Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther. 8:582-591. DOI.
  • Essafi A; Gomes AR; Pomeranz KM; Zwolinska AK; Varshochi R; McGovern UB; Lam EW. (2009). Studying the subcellular localization and DNA-binding activity of FoxO transcription factors, downstream effectors of PI3K/Akt. Methods Mol Biol. 462:201-211.
  • Gomes AR; Brosens JJ; Lam EW. (Oct 2008). Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle. 7:3133-3136.
  • Hui RC; Gomes AR; Constantinidou D; Costa JR; Karadedou CT; Fernandez de Mattos S; Wymann MP; Brosens JJ; et alSchulze A; Lam EW. (Oct 2008). The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol. 28:5886-5898. DOI.
  • Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW. (Jul 2008). Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther. 7:2022-2032. DOI.
  • Li SK; Smith DK; Leung WY; Cheung AM; Lam EW; Dimri GP; Yao KM. (13 Jun 2008). FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. J Biol Chem. 283:16545-16553. DOI.
  • Cloke B; Huhtinen K; Fusi L; Kajihara T; Yliheikkilä M; Ho KK; Teklenburg G; Lavery S; et alJones MC; Trew G; Kim JJ; Lam EW; Cartwright JE; Poutanen M; Brosens JJ. (Sep 2008). The androgen and progesterone receptors regulate distinct gene networks and cellular functions in decidualizing endometrium. Endocrinology. 149:4462-4474. DOI.
  • Ho KK; Myatt SS; Lam EW. (7 Apr 2008). Many forks in the path: cycling with FoxO. Oncogene. 27:2300-2311. DOI.
  • Hui RC; Francis RE; Guest SK; Costa JR; Gomes AR; Myatt SS; Brosens JJ; Lam EW. (Mar 2008). Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther. 7:670-678. DOI.
  • Myatt SS; Lam EW. (Mar 2008). Targeting FOXM1. Nat Rev Cancer. 8:242. DOI.
  • Ho KK; Anderson AA; Rosivatz E; Lam EW; Woscholski R; Mann DJ. (29 Feb 2008). Identification of cyclin A2 as the downstream effector of the nuclear phosphatidylinositol 4,5-bisphosphate signaling network. J Biol Chem. 283:5477-5485. DOI.
  • Goto T; Takano M; Albergaria A; Briese J; Pomeranz KM; Cloke B; Fusi L; Feroze-Zaidi F; et alMaywald N; Sajin M; Dina RE; Ishihara O; Takeda S; Lam EW; Bamberger AM; Ghaem-Maghami S; Brosens JJ. (3 Jan 2008). Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene. 27:9-19. DOI.
  • Krol J; Francis RE; Albergaria A; Sunters A; Polychronis A; Coombes RC; Lam EW. (Dec 2007). The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther. 6:3169-3179. DOI.
  • Myatt SS; Lam EW. (Nov 2007). The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847-859. DOI.
  • Feroze-Zaidi F; Fusi L; Takano M; Higham J; Salker MS; Goto T; Edassery S; Klingel K; et alBoini KM; Palmada M; Kamps R; Groothuis PG; Lam EW; Smith SK; Lang F; Sharkey AM; Brosens JJ. (Oct 2007). Role and regulation of the serum- and glucocorticoid-regulated kinase 1 in fertile and infertile human endometrium. Endocrinology. 148:5020-5029. DOI.
  • Takano M; Lu Z; Goto T; Fusi L; Higham J; Francis J; Withey A; Hardt J; et alCloke B; Stavropoulou AV; Ishihara O; Lam EW; Unterman TG; Brosens JJ; Kim JJ. (Oct 2007). Transcriptional cross talk between the forkhead transcription factor forkhead box O1A and the progesterone receptor coordinates cell cycle regulation and differentiation in human endometrial stromal cells. Mol Endocrinol. 21:2334-2349. DOI.
  • Delpuech O; Griffiths B; East P; Essafi A; Lam EW; Burgering B; Downward J; Schulze A. (Jul 2007). Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Mol Cell Biol. 27:4917-4930. DOI.
  • Zhao C; Matthews J; Tujague M; Wan J; Ström A; Toresson G; Lam EW; Cheng G; et alGustafsson JA; Dahlman-Wright K. (2007). Estrogen receptor (ER) β2 negatively regulates the transactivation of ERα in human breast cancer cells. Cancer Res. 67:3955-3962.
  • Muñoz-Fontela C; Marcos-Villar L; Gallego P; Arroyo J; Da Costa M; Pomeranz KM; Lam EW; Rivas C. (Feb 2007). Latent protein LANA2 from Kaposi's sarcoma-associated herpesvirus interacts with 14-3-3 proteins and inhibits FOXO3a transcription factor. J Virol. 81:1511-1516. DOI.
  • Ramasamy R; Lam EW; Soeiro I; Tisato V; Bonnet D; Dazzi F. (Feb 2007). Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia. 21:304-310. DOI.
  • Ramasamy R; Fazekasova H; Lam EW; Soeiro I; Lombardi G; Dazzi F. (15 Jan 2007). Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 83:71-76. DOI.
  • Myatt SS; Lam EW. (2007). Promiscuous and lineage-specific roles of cell cycle regulators in haematopoiesis. Cell Div. 2:6. DOI.
  • Rosivatz E; Matthews JG; McDonald NQ; Mulet X; Ho KK; Lossi N; Schmid AC; Mirabelli M; et alPomeranz KM; Erneux C; Lam EW; Vilar R; Woscholski R. (15 Dec 2006). A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol. 1:780-790. DOI.
  • Krietsch T; Fernandes MS; Kero J; Lösel R; Heyens M; Lam EW; Huhtaniemi I; Brosens JJ; et alGellersen B. (Dec 2006). Human homologs of the putative G protein-coupled membrane progestin receptors (mPRalpha, beta, and gamma) localize to the endoplasmic reticulum and are not activated by progesterone. Mol Endocrinol. 20:3146-3164. DOI.
  • Birkenkamp KU; Essafi A; van der Vos KE; Da Costa M; Hui RC; Holstege F; Koenderman L; Lam EW; et alCoffer PJ. (2007). FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. J Biol Chem. 282:2211-2220.
  • van Gorp AG; Pomeranz KM; Birkenkamp KU; Hui RC; Lam EW; Coffer PJ. (15 Nov 2006). Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation. Cancer Res. 66:10760-10769. DOI.
  • Shore AM; White PC; Hui RC; Essafi A; Lam EW; Rowe M; Brennan P. (Nov 2006). Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A. J Virol. 80:11191-11199. DOI.
  • Lam EW; Francis RE; Petkovic M. (Nov 2006). FOXO transcription factors: key regulators of cell fate. Biochem Soc Trans. 34:722-726. DOI.
  • Jones MC; Fusi L; Higham JH; Abdel-Hafiz H; Horwitz KB; Lam EW; Brosens JJ. (31 Oct 2006). Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. Proc Natl Acad Sci U S A. 103:16272-16277. DOI.
  • Kajihara T; Jones M; Fusi L; Takano M; Feroze-Zaidi F; Pirianov G; Mehmet H; Ishihara O; et alHigham JM; Lam EW; Brosens JJ. (Oct 2006). Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. Mol Endocrinol. 20:2444-2455. DOI.
  • Madureira PA; Varshochi R; Constantinidou D; Francis RE; Coombes RC; Yao KM; Lam EW. (1 Sep 2006). The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem. 281:25167-25176. DOI.
  • Leyton J; Alao JP; Da Costa M; Stavropoulou AV; Latigo JR; Perumal M; Pillai R; He Q; et alAtadja P; Lam EW; Workman P; Vigushin DM; Aboagye EO. (1 Aug 2006). In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Cancer Res. 66:7621-7629. DOI.
  • Soeiro I; Mohamedali A; Romanska HM; Lea NC; Child ES; Glassford J; Orr SJ; Roberts C; et alNaresh KN; Lalani ELN; Mann DJ; Watson RJ; Thomas NS; Lam EW. (Aug 2006). p27Kip1 and p130 cooperate to regulate hematopoietic cell proliferation in vivo. Mol Cell Biol. 26:6170-6184. DOI.
  • Hills FA; Abrahams VM; González-Timón B; Francis J; Cloke B; Hinkson L; Rai R; Mor G; et alRegan L; Sullivan M; Lam EW; Brosens JJ. (Apr 2006). Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod. 12:237-243. DOI.
  • Brosens JJ; Lam EW; Parker MG. (10 Feb 2006). Inflammation and sex steroid receptors: a motif for change. Cell. 124:466-468. DOI.
  • Alao JP; Stavropoulou AV; Lam EW; Coombes RC; Vigushin DM. (2006). Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer. 5:8. DOI.
  • Sunters A; Madureira PA; Pomeranz KM; Aubert M; Brosens JJ; Cook SJ; Burgering BM; Coombes RC; et alLam EW. (1 Jan 2006). Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res. 66:212-220. DOI.
  • Labied S; Kajihara T; Madureira PA; Fusi L; Jones MC; Higham JM; Varshochi R; Francis JM; et alZoumpoulidou G; Essafi A; Fernandez de Mattos S; Lam EW; Brosens JJ. (Jan 2006). Progestins regulate the expression and activity of the forkhead transcription factor FOXO1 in differentiating human endometrium. Mol Endocrinol. 20:35-44. DOI.
  • Alao JP; Gamble SC; Stavropoulou AV; Pomeranz KM; Lam EW; Coombes RC; Vigushin DM. (2006). The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer. 5:7. DOI.
  • Madureira PA; Matos P; Soeiro I; Dixon LK; Simas JP; Lam EW. (11 Nov 2005). Murine gamma-herpesvirus 68 latency protein M2 binds to Vav signaling proteins and inhibits B-cell receptor-induced cell cycle arrest and apoptosis in WEHI-231 B cells. J Biol Chem. 280:37310-37318. DOI.
  • Fernandes MS; Pierron V; Michalovich D; Astle S; Thornton S; Peltoketo H; Lam EW; Gellersen B; et alHuhtaniemi I; Allen J; Brosens JJ. (Oct 2005). Regulated expression of putative membrane progestin receptor homologues in human endometrium and gestational tissues. J Endocrinol. 187:89-101. DOI.
  • Glassford J; Vigorito E; Soeiro I; Madureira PA; Zoumpoulidou G; Brosens JJ; Turner M; Lam EW. (Sep 2005). Phosphatidylinositol 3-kinase is required for the transcriptional activation of cyclin D2 in BCR activated primary mouse B lymphocytes. Eur J Immunol. 35:2748-2761. DOI.
  • Dunne PJ; Belaramani L; Fletcher JM; Fernandez de Mattos S; Lawrenz M; Soares MV; Rustin MH; Lam EW; et alSalmon M; Akbar AN. (15 Jul 2005). Quiescence and functional reprogramming of Epstein-Barr virus (EBV)-specific CD8+ T cells during persistent infection. Blood. 106:558-565. DOI.
  • Glennie S; Soeiro I; Dyson PJ; Lam EW; Dazzi F. (1 Apr 2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 105:2821-2827. DOI.
  • Essafi A; Fernández de Mattos S; Hassen YA; Soeiro I; Mufti GJ; Thomas NS; Medema RH; Lam EW. (31 Mar 2005). Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene. 24:2317-2329. DOI.
  • Varshochi R; Halim F; Sunters A; Alao JP; Madureira PA; Hart SM; Ali S; Vigushin DM; et alCoombes RC; Lam EW. (4 Feb 2005). ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem. 280:3185-3196. DOI.
  • Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; et alCoombes RC; Vigushin DM. (1 Dec 2004). Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res. 10:8094-8104. DOI.
  • Fernández de Mattos S; Essafi A; Soeiro I; Pietersen AM; Birkenkamp KU; Edwards CS; Martino A; Nelson BH; et alFrancis JM; Jones MC; Brosens JJ; Coffer PJ; Lam EW. (Nov 2004). FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol. 24:10058-10071. DOI.
  • Vigorito E; Bardi G; Glassford J; Lam EW; Clayton E; Turner M. (1 Sep 2004). Vav-dependent and vav-independent phosphatidylinositol 3-kinase activation in murine B cells determined by the nature of the stimulus. J Immunol. 173:3209-3214.
  • Zoumpoulidou G; Jones MC; Fernandez de Mattos S; Francis JM; Fusi L; Lee YS; Christian M; Varshochi R; et alLam EW; Brosens JJ. (Aug 2004). Convergence of interferon-gamma and progesterone signaling pathways in human endometrium: role of PIASy (protein inhibitor of activated signal transducer and activator of transcription-y). Mol Endocrinol. 18:1988-1999. DOI.
  • Palmieri C; Saji S; Sakaguchi H; Cheng G; Sunters A; O'Hare MJ; Warner M; Gustafsson JA; et alCoombes RC; Lam EW. (Aug 2004). The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. J Mol Endocrinol. 33:35-50.
  • Palmieri C; Lam EW; Vigushin D; Coombes RC. (1 May 2004). Value of SERMs in postmenopausal women. Lancet. 363:1477-1478. DOI.
  • Gamble SC; Odontiadis M; Waxman J; Westbrook JA; Dunn MJ; Wait R; Lam EW; Bevan CL. (15 Apr 2004). Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene. 23:2996-3004. DOI.
  • Brosens JJ; Tullet J; Varshochi R; Lam EW. (Apr 2004). Steroid receptor action. Best Pract Res Clin Obstet Gynaecol. 18:265-283. DOI.
  • Palmieri C; Lam EW; Mansi J; MacDonald C; Shousha S; Madden P; Omoto Y; Sunters A; et alWarner M; Gustafsson JA; Coombes RC. (1 Apr 2004). The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res. 10:2421-2428.
  • Sunters A; Fernández de Mattos S; Stahl M; Brosens JJ; Zoumpoulidou G; Saunders CA; Coffer PJ; Medema RH; et alCoombes RC; Lam EW. (12 Dec 2003). FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 278:49795-49805. DOI.
  • Mohamedali A; Soeiro I; Lea NC; Glassford J; Banerji L; Mufti GJ; Lam EW; Thomas NS. (Dec 2003). Cyclin D2 controls B cell progenitor numbers. J Leukoc Biol. 74:1139-1143. DOI.
  • Zhao C; Lam EW; Sunters A; Enmark E; De Bella MT; Coombes RC; Gustafsson JA; Dahlman-Wright K. (23 Oct 2003). Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene. 22:7600-7606. DOI.
  • Glassford J; Soeiro I; Skarell SM; Banerji L; Holman M; Klaus GG; Kadowaki T; Koyasu S; et alLam EW. (17 Apr 2003). BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells. Oncogene. 22:2248-2259. DOI.
  • Lea NC; Orr SJ; Stoeber K; Williams GH; Lam EW; Ibrahim MA; Mufti GJ; Thomas NS. (Apr 2003). Commitment point during G0-->G1 that controls entry into the cell cycle. Mol Cell Biol. 23:2351-2361.
  • Palmieri C; Roberts-Clark D; Assadi-Sabet A; Coope RC; O'Hare M; Sunters A; Hanby A; Slade MJ; et alGomm JJ; Lam EW; Coombes RC. (Apr 2003). Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cells. J Endocrinol. 177:65-81.
  • Fernández de Mattos S; Lam EW; Tauler A. (15 Nov 2002). An E2F-binding site mediates the activation of the proliferative isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase by phosphatidylinositol 3-kinase. Biochem J. 368:283-291. DOI.
  • Schmidt M; Fernandez de Mattos S; van der Horst A; Klompmaker R; Kops GJ; Lam EW; Burgering BM; Medema RH. (Nov 2002). Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol. 22:7842-7852.
  • Chopra S; Fernandez De Mattos S; Lam EW; Mann DJ. (6 Sep 2002). Jab1 co-activation of c-Jun is abrogated by the serine 10-phosphorylated form of p27Kip1. J Biol Chem. 277:32413-32416. DOI.
  • Barnouin K; Dubuisson ML; Child ES; Fernandez de Mattos S; Glassford J; Medema RH; Mann DJ; Lam EW. (19 Apr 2002). H2O2 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression. J Biol Chem. 277:13761-13770. DOI.
  • Kops GJ; Medema RH; Glassford J; Essers MA; Dijkers PF; Coffer PJ; Lam EW; Burgering BM. (Apr 2002). Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol. 22:2025-2036.
  • Dijkers PF; Birkenkamp KU; Lam EW; Thomas NS; Lammers JW; Koenderman L; Coffer PJ. (4 Feb 2002). FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol. 156:531-542. DOI.
  • Glassford J; Holman M; Banerji L; Clayton E; Klaus GG; Turner M; Lam EW. (2 Nov 2001). Vav is required for cyclin D2 induction and proliferation of mouse B lymphocytes activated via the antigen Receptor. J Biol Chem. 276:41040-41048. DOI.
  • Banerji L; Glassford J; Lea NC; Thomas NS; Klaus GG; Lam EW. (1 Nov 2001). BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells. Oncogene. 20:7352-7367. DOI.
  • Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; et alGoldman JM; Melo JV. (1 Nov 2001). Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res. 61:8005-8013.
  • Parada Y; Banerji L; Glassford J; Lea NC; Collado M; Rivas C; Lewis JL; Gordon MY; et alThomas NS; Lam EW. (29 Jun 2001). BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem. 276:23572-23580. DOI.
  • Rivas C; Miller AR; Collado M; Lam EW; Apperley JF; Melo JV. (May 2001). BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir. Mol Ther. 3:642-652. DOI.
  • Lewis JL; Chinswangwatanakul W; Zheng B; Marley SB; Nguyen DX; Cross NC; Banerji L; Glassford J; et alThomas NS; Goldman JM; Lam EW; Gordon MY. (1 May 2001). The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells. Blood. 97:2604-2610.
  • Dijkers PF; Medema RH; Pals C; Banerji L; Thomas NS; Lam EW; Burgering BM; Raaijmakers JA; et alLammers JW; Koenderman L; Coffer PJ. (Dec 2000). Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol. 20:9138-9148.
  • Kirkham PA; Takamatsu HH; Lam EW; Parkhouse RM. (1 Oct 2000). Ligation of the WC1 receptor induces gamma delta T cell growth arrest through fumonisin B1-sensitive increases in cellular ceramide. J Immunol. 165:3564-3570.
  • Collado M; Medema RH; Garcia-Cao I; Dubuisson ML; Barradas M; Glassford J; Rivas C; Burgering BM; et alSerrano M; Lam EW. (21 Jul 2000). Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem. 275:21960-21968. DOI.
  • Solvason N; Wu WW; Parry D; Mahony D; Lam EW; Glassford J; Klaus GG; Sicinski P; et alWeinberg R; Liu YJ; Howard M; Lees E. (May 2000). Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol. 12:631-638.
  • Lam EW; Glassford J; Banerji L; Thomas NS; Sicinski P; Klaus GG. (4 Feb 2000). Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem. 275:3479-3484.
  • Powell AJ; Darmon AJ; Gonos ES; Lam EW; Peden KW; Jat PS. (2 Dec 1999). Different functions are required for initiation and maintenance of immortalization of rat embryo fibroblasts by SV40 large T antigen. Oncogene. 18:7343-7350. DOI.
  • Lam EW; Glassford J; van der Sman J; Banerji L; Pizzey AR; Shaun N; Thomas B; Klaus GG. (Oct 1999). Modulation of E2F activity in primary mouse B cells following stimulation via surface IgM and CD40 receptors. Eur J Immunol. 29:3380-3389. DOI.
  • van der Sman J; Thomas NS; Lam EW. (23 Apr 1999). Modulation of E2F complexes during G0 to S phase transition in human primary B-lymphocytes. J Biol Chem. 274:12009-12016.
  • Voorhoeve PM; Watson RJ; Farlie PG; Bernards R; Lam EW. (21 Jan 1999). Rapid dephosphorylation of p107 following UV irradiation. Oncogene. 18:679-688. DOI.
  • Kirkham PA; Lam EW; Takamatsu HH; Parkhouse RM. (15 Aug 1998). Transcription factor E2F controls the reversible gamma delta T cell growth arrest mediated through WC1. J Immunol. 161:1630-1636.
  • Gopalkrishnan RV; Lam EW; Kedinger C. (1 May 1998). The p53 tumor suppressor inhibits transcription of the TATA-less mouse DP1 promoter. J Biol Chem. 273:10972-10978.
  • Lam EW; Choi MS; van der Sman J; Burbidge SA; Klaus GG. (17 Apr 1998). Modulation of E2F activity via signaling through surface IgM and CD40 receptors in WEHI-231 B lymphoma cells. J Biol Chem. 273:10051-10057.
  • Klaus GG; Choi MS; Lam EW; Johnson-Léger C; Cliff J. (1997). CD40: a pivotal receptor in the determination of life/death decisions in B lymphocytes. Int Rev Immunol. 15:5-31.
  • O'Connor DJ; Lam EW; Griffin S; Zhong S; Leighton LC; Burbidge SA; Lu X. (15 Dec 1995). Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J. 14:6184-6192.
  • Hao XF; Alphey L; Bandara LR; Lam EW; Glover D; La Thangue NB. (Sep 1995). Functional conservation of the cell cycle-regulating transcription factor DRTF1/E2F and its pathway of control in Drosophila melanogaster. J Cell Sci. 108 ( Pt 9):2945-2954.
  • Lam EW; Bennett JD; Watson RJ. (28 Jul 1995). Cell-cycle regulation of human B-myb transcription. Gene. 160:277-281.
  • Jooss K; Lam EW; Bybee A; Girling R; Müller R; La Thangue NB. (20 Apr 1995). Proto-oncogenic properties of the DP family of proteins. Oncogene. 10:1529-1536.
  • Lam EW; La Thangue NB. (Dec 1994). DP and E2F proteins: coordinating transcription with cell cycle progression. Curr Opin Cell Biol. 6:859-866.
  • Girling R; Bandara LR; Ormondroyd E; Lam EW; Kotecha S; Mohun T; La Thangue NB. (Oct 1994). Molecular characterization of Xenopus laevis DP proteins. Mol Biol Cell. 5:1081-1092.
  • Bandara LR; Lam EW; Sørensen TS; Zamanian M; Girling R; La Thangue NB. (1 Jul 1994). DP-1: a cell cycle-regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein. EMBO J. 13:3104-3114.
  • Lam EW; Morris JD; Davies R; Crook T; Watson RJ; Vousden KH. (15 Feb 1994). HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes. EMBO J. 13:871-878.
  • Lam EW; Watson RJ. (Jul 1993). An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription. EMBO J. 12:2705-2713.
  • Watson RJ; Robinson C; Lam EW. (25 Jan 1993). Transcription regulation by murine B-myb is distinct from that by c-myb. Nucleic Acids Res. 21:267-272.
  • Lam EW; Robinson C; Watson RJ. (Sep 1992). Characterization and cell cycle-regulated expression of mouse B-myb. Oncogene. 7:1885-1890.

Books

  • Eric W-F Lam. Lam EW-F (ed). Phosphoinositide 3-Kinase Signalling Pathway: The Key to Cell Proliferation and Death. 1. World Scientific Press, Singapore (2006).

Chapters in books

  • Andrew Sunters; Eric W-F Lam. Cell Proliferation and Cell Death. In Phosphoinositide 3-Kinase Signalling Pathway: The Key to Cell Proliferation and Death. 1. Lam EW-F (ed). World Scientific Press (2006).
  • Silvia Fernandez de Mattos, Jan J. Brosens and Eric W.-F. Lam. FOXO transcription factors. In Phosphoinositide 3-Kinase Signalling Pathway: The Key to Cell Proleration and Death. Lam EW-F (ed). World Scientific Press, Singapore (2006).
  • Eric W-F Lam. Phosphoinositide 3-Kinase Signalling Pathway. In Phosphoinositide 3-Kinase Signalling Pathway: The Key to Cell Proliferation and Death. Lam EW-F (ed). World Scientic Press (2006).

Conferences

  • McKie A; Vaughan S; Okon I; Zanini E; Al-Jayoosi F; Agarwal R; Lam EWF; Gabra H. The OPCML tumour suppressor functions as a repressor-adaptor, negatively regulating receptor tyrosine kinases in ovarian cancer. 21st Meeting of the European-Association-for-Cancer-Research, 26 Jun 2010 - 29 Jun 2010. 8:108-108. PERGAMON-ELSEVIER SCIENCE LTD (1 Jun 2010).
  • Millour J; Lam EW. FOXM1 is a transcriptional target of ERa and has a critical role in breast cancer endocrine sensitivity and resistance. Conference on Breast Cancer Research, 18 May 2010. 12:S3-S3. BIOMED CENTRAL LTD (1 Jan 2010). Author weblink DOI.
  • Batlle A; Papadopoulou V; Gomes AR; Willimott S; Melo JV; Naresh K; Lam EW; Wagner SD. MEMBRANE AND SOLUBLE CD40 LIGAND HAVE DIFFERENT EFFECTS ON BCL-6 EXPRESSION AND PRODUCE DIFFERENT PROTEIN/DNA COMPLEXES AT A SITE IN EXON 1 OF THE BCL-6 GENE. 14th Annual Meeting of the European-Hematology-Association, 4 Jun 2009 - 7 Jun 2009. 94:229-229. FERRATA STORTI FOUNDATION (1 Jun 2009). Author weblink.
  • Batlle A; Lam EW; Wagner SD. Bcl-6 may be a survival factor in Pre-b cell Ph plus blast crisis cell lines. 49th Annual Meeting of the American-Society-of-Hematology. 110:206B-206B. (16 Nov 2007).
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook